CARDIOASPIRIN ® Acetylsalicylic acid

CARDIOASPIRIN ® is a drug based on acetylsalicylic acid.

THERAPEUTIC GROUP: Antithrombotic.

Indications CARDIOASPIRIN ® Acetylsalicylic acid

CARDIOASPIRIN ® is used for preventive purposes to reduce the incidence of coronary thrombosis after myocardial infarction, in patients with increased risk and suffering from angina pectoris, arterial hypertension, hypercholesterolemia, obesity, diabetes mellitus and family history of heart disease.
CARDIOASPIRIN ® is also useful in the prophylaxis of ischemic events after cerebral stroke, re-occlusion of aorto-coronary bypasses and after angioplasty; it can also be used successfully in the prevention of thrombotic events caused by extracorporeal circulation.

Mechanism of action CARDIOASPIRIN ® Acetylsalicylic acid

The oral intake of acetylsalicylic acid, using CARDIOASPIRIN ® allows the achievement of maximum plasma concentrations in delayed time intervals compared to the intake without gastroresistant envelope; all without the achievement of high blood levels, given the gradual release of the active principle. This pharmacokinetic characteristic, accompanied by a modest dosage, allows acetylsalicylic acid to be metabolized only in a small part by intestinal and hepatic esterases, thus preserving its antithrombotic properties rather than analgesic ones.
In fact, the intact active ingredient, not yet metabolized to salicylic acid and derivatives, can inhibit platelet aggregation by blocking the cyclo-oxygenase enzyme, which at the platelet level mediates the transition from arachidonic acid to thromboxane A2, responsible for platelet aggregation and of vasoconstriction.
This inhibition will be permanent, given the inability of the (anucleated) platelets to synthesize new messengers useful for the synthesis of thromboxane A2.
After a rapid half-life, estimated around 15 minutes, which nevertheless guarantees an important antithrombotic action, acetylsalicylic acid is readily hydrolyzed by hepatic esterases into salicylic acid and derivatives, which will then be excreted mainly through the urine.

Studies carried out and clinical efficacy

ANTI-CANCER ACTION OF SALICYL ACETYL ACID

Cancer Sci. 2010 Oct; 101: 2105-9.

Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients

Bhattacharyya M, Girish GV, Ghosh R, Chakraborty S, Sinha AK.

The daily ingestion of cardioasprin in patients with previously treated breast carcinoma allowed to observe a significant increase in the levels of maspin, a protein involved in the inhibition of the metastatic evolution of breast cancer. The observed elevated levels of maspin (from 9nM to 4.6 nM), could represent an important preventive factor in the development of metastases.

2.EFFICACY OF THE ACETYLSALICYL ACID-CLOPIDROGEL COMBINED THERAPY

Heart Vessels. 2010 Dec 23.

Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study.

Awidi A, Saleh A, Dweik M, Kailani B, Abu-Fara M, Nabulsi R, Bener A.

This annual study conducted on about 300 patients with cardiovascular diseases, with an increased risk of thrombotic events, evaluated the efficacy of antithrombotic therapy with acetylsalicylic acid, clopidogrel or combined therapy. The results show greater efficacy, with better therapeutic control on the " platelet aggregation, when the two active ingredients are administered simultaneously.

3. ANTIATEROSCLEROTIC ACTION OF SALICYL ACETYL ACID

Atherosclerosis. 2007 Apr; 191: 272-5. Epub 2006 Jun 21.

Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis.

Santanam N, Parthasarathy S.

Molecular studies conducted on the activity of an enzyme known as PON1 (paraoxonase 1), have shown that among its substrates there may also be acetylsalicylic acid. The esterase action of this enzyme is necessary for the synthesis of active metabolites starting from acetylsalicylic acid, experimentally involved in a direct antioxidant action. This mechanism could be the basis of the protective action of this active ingredient.

Method of use and dosage

CARDIOASPIRIN ® 100mg gastro-resistant coated tablets of acetylsalicylic acid: the most used dosage is that of one daily tablet, taken with plenty of water before meals.
Any dosage corrections must be evaluated by the doctor after a "careful evaluation of the patient's physio-pathological picture.

IN ANY CASE, BEFORE TAKING CARDIOASPIRIN ® Acetylsalicylic acid - YOU MUST BE REQUIRED AND CHECK FROM YOUR DOCTOR.

Warnings CARDIOASPIRIN ® Acetylsalicylic acid

CARDIOASPIRIN ® should be taken with particular care in patients with impaired renal and hepatic function, or undergoing anticoagulant therapy.
Acetylsalicylic acid should not be taken by patients sensitive to salicylates or other anti-inflammatory drugs, in order to avoid unpleasant allergic reactions and gastrointestinal bleeding.
CARDIOASPIRIN ® does not affect the ability to drive vehicles or use machines.

PREGNANCY AND BREASTFEEDING

The administration of therapeutic doses of acetylsalicylic acid, in an obstretic-gynecological setting and under strict medical-specialist supervision, did not cause the onset of side effects for the health of the fetus.
Otherwise, prolonged use during lactation should be followed by discontinuation of breastfeeding of the infant.

Interactions

The therapeutic action of acetylsalicylic acid could be altered by the concomitant administration of anticoagulants, immunosuppressive drugs, antihypertensive drugs, painkillers such as ibuprofen, non-steroidal anti-inflammatory drugs, antigout drugs and anticancer drugs.
On the contrary, CARDIOASPIRIN ® could alter the efficacy of anticoagulants, corticosteroids, analgesics, hypoglycemic agents, methotrexate, furosemide and spironolactone, increasing the incidence of potentially dangerous side effects for the patient's health.

Contraindications CARDIOASPIRIN ® Acetylsalicylic acid

The use of CARDIOASPIRIN ® is contraindicated in patients with an increased risk of haemorrhages and gastropathies. The hepatic metabolism and renal excretion make it necessary to avoid the use of this drug even in case of renal or hepatic insufficiency.
CARDIOASPIRIN ® should not be used in the course of viral diseases in pediatric patients, as it is at risk of an enhancement of the toxic effects of the various toxins, with consequent Reye's syndrome; analogous discourse in patients hypersensitive to acetylsalicylic acid, salicylates and its excipients.

Undesirable Effects - Side Effects

CARDIOASPIRIN ® was well tolerated, with the description of cardiovascular events predominantly in sensitive patients. In the same, but with a significantly reduced frequency, gastrointestinal bleeding episodes and thrombocytopenia were observed.

Note

CARDIOASPIRIN ® can only be sold under medical prescription.

The information on CARDIOASPIRIN ® Acetylsalicylic acid published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.